A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing–remitting multiple sclerosis

Background: Mycophenolate mofetil (MMF, CellCept®) has been utilized as an antirejection agent in transplant recipients and in patients with myriad autoimmune disorders including multiple sclerosis (MS). Objective: To investigate radiographic and clinical safety involving monotherapy use of daily or...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Frohman, Elliot M., Cutter, Gary, Remington, Gina, Gao, Hongjiang, Rossman, Howard, Weinstock-Guttman, Bianca, Durfee, Jacqueline E., Conger, Amy, Carl, Ellen, Treadaway, Katherine, Lindzen, Eric, Salter, Amber, Frohman, Teresa C., Shah, Anjali, Bates, Angela, Cox, Jennifer L., Dwyer, Michael G., Stüve, Olaf, Greenberg, Benjamin M., Racke, Michael K., Zivadinov, Robert
التنسيق: Artigo
اللغة:Inglês
منشور في: SAGE Publications 2010
الموضوعات:
Original Research
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3002613/
https://ncbi.nlm.nih.gov/pubmed/21180633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285609353354
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة